1
Danahay Henry Luke, Legrand Darren Mark, Tully David C, Harris Jennifer Leslie, Heuerding Silvia, Singh Dilraj, Maas Janet Catherine, Roettele Juergen, Reber Jean Louis, Monnier Stéphanie: Organic compounds. Novartis, Novartis Pharma, Irm, Danahay Henry Luke, Legrand Darren Mark, Tully David C, Harris Jennifer Leslie, Heuerding Silvia, Singh Dilraj, Maas Janet Catherine, Roettele Juergen, Reber Jean Louis, Monnier Stéphanie, LEON Susanna, October 19, 2006: WO/2006/108643 (5 worldwide citation)

The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmo ...


2
Tully David C, Chatterjee Arnab K, Petrassi Hank Michael James, Bursulaya Badry, Spraggon Glen: Compounds and compositions as channel activating protease inhibitors. Irm, Tully David C, Chatterjee Arnab K, Petrassi Hank Michael James, Bursulaya Badry, Spraggon Glen, SMITH Timothy L, December 6, 2007: WO/2007/140117 (5 worldwide citation)

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostas ...


3
Tully David C, Chatterjee Arnab K, Vidal Agnes, Petrassi Hank Michael James, Wang Zhiwei, Bursulaya Badry, Spraggon Glen: Compounds and compositions as channel activating protease inhibitors. Irm, Tully David C, Chatterjee Arnab K, Vidal Agnes, Petrassi Hank Michael James, Wang Zhiwei, Bursulaya Badry, Spraggon Glen, TONGCO WU Emily, November 29, 2007: WO/2007/137080 (4 worldwide citation)

The invention provides compounds of formula (1) and pharmaceutically acceptable salts, hydrates, solvates, stereoisomers and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a cond ...


4
Tully David C, Chatterjee Arnab K, Vidal Agnes, Bursulaya Badry, Spraggon Glen: Compounds and compositions as channel activating protease inhibitors. Irm, Tully David C, Chatterjee Arnab K, Vidal Agnes, Bursulaya Badry, Spraggon Glen, TONGCO WU Emily, July 17, 2008: WO/2008/085608 (3 worldwide citation)

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prosta ...


5
Tully David C, Chatterjee Arnab K, Wang Zhiwei: Compounds and compositions as channel activating protease inhibitors. Irm, Tully David C, Chatterjee Arnab K, Wang Zhiwei, TONGCO WU Emily, August 14, 2008: WO/2008/097676 (3 worldwide citation)

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prosta ...


6
Tully David C, Chatterjee Arnab K, Vidal Agnes, Bursulaya Badry: Compounds and compositions as channel activating protease inhibitors. Irm, Tully David C, Chatterjee Arnab K, Vidal Agnes, Bursulaya Badry, TONGCO WU Emily, August 14, 2008: WO/2008/097673 (3 worldwide citation)

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostas ...


7
Liu Hong, Tully David C, Chatterjee Arnab, Alper Phillip B, Woodmansee David H, Mutnick Daniel: Compounds and compositions as cathepsin s inhibitors. Irm, Liu Hong, Tully David C, Chatterjee Arnab, Alper Phillip B, Woodmansee David H, Mutnick Daniel, REID Scott W, November 17, 2005: WO/2005/107464 (1 worldwide citation)

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.


8
TULLY David C, RUCKER Paul Vincent, ALPER Phillip B, MUTNICK Daniel, CHIANELLI Donatella: COMPOSITIONS ET PROCÉDÉS POUR LA MODULATION DE FXR, COMPOSITIONS AND METHODS FOR MODULATING FXR. IRM, TULLY David C, RUCKER Paul Vincent, ALPER Phillip B, MUTNICK Daniel, CHIANELLI Donatella, TONGCO WU Emily, June 28, 2012: WO/2012/087519 (1 worldwide citation)

The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X ...


9
Mainquist James Kevin, Geierstanger Bernhard H, Tully David C: Apparatus and methods to process substrate surface features. Irm, Mainquist James Kevin, Geierstanger Bernhard H, Tully David C, QUINE Jonathan Alain, May 27, 2004: WO/2004/044121

The present invention provides apparatus (100) for fluidly separating substrate surface features. The apparatus includs arrays of apertures (104) that correspond to at least a portion of an array of wells (104) disposed in a micro-well plate and/or structure to fluidically separate multiple surface ...


10
Liu Hong, Chatterjee Arnab, Tully David C, Alper Phillip B, Bursulaya Badry, Guo Jianhua, Woodmansee David, Mutnick Daniel, Karanewsky Donald S, He Yun: Inhibitors of cathepsin s. Irm, Liu Hong, Chatterjee Arnab, Tully David C, Alper Phillip B, Bursulaya Badry, Guo Jianhua, Woodmansee David, Mutnick Daniel, Karanewsky Donald S, He Yun, SNYDER Joseph R, April 21, 2005: WO/2005/034848

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease stat ...